SavedAdd your journal

Journals / Clinical and Experimental Health Sciences / 2019 / Cilt: 9 - Sayı: 4

An Overview of Experimental Models on Ischemic Heart Diseases

Ahmet Özer Şehirli
Demet Sinem Güden
Pages
358–365
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Given the wide range of models available, the future animal models of ischemic heart failure will potentially provide more efficient and reliable preventative measures in the fight against complex cardiovascular diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Heart failure is commonly defined as a heart dysfunction associated with pulmonary alveolar blood flow and consequent inability to ensure adequate blood supply to the tissues or to meet the body’s metabolic demand.
📊
Key Findings & Data:These models were designed to generate global and regional ischemia.Our review is conducted to evaluate experimental models with the intent of improving the modelling of ischemic heart diseases.
💡
Conclusion & Impact:Given the wide range of models available, the future animal models of ischemic heart failure will potentially provide more efficient and reliable preventative measures in the fight against complex cardiovascular diseases.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:ischemia/reperfusion · heart failure · cardiomyophaty

Abstract

Objective: Heart failure is commonly defined as a heart dysfunction associated with pulmonary alveolar blood flow and consequent inability to ensure adequate blood supply to the tissues or to meet the body’s metabolic demand. Currently, there is a considerable lack of experimental uniformity for ischemic heart models as well as types of ischemia. Therefore, our objective is to summarize frequently applied methods that are designed to evaluate ischemic heart diseases. A systematic search was conducted to review experimental models according to keywords. In general, iatrogenic and transgenic cardiomyopathy models were used in the literature. These models were designed to generate global and regional ischemia.Our review is conducted to evaluate experimental models with the intent of improving the modelling of ischemic heart diseases. Poor modelling can contribute to high mortality and morbidity rates in cardiology. Given the wide range of models available, the future animal models of ischemic heart failure will potentially provide more efficient and reliable preventative measures in the fight against complex cardiovascular diseases.

🔖

Cite This Article

Şehirli, A. Ö., Güden, D. S. (2022). An Overview of Experimental Models on Ischemic Heart Diseases. Clinical and Experimental Health Sciences, Cilt: 9 - Sayı: 4, 358–365. https://ajindex.com/articles/474357

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kadayıfcı A. UTS Dahiliye. 4th ed. Ankara:Atlas Kitapcılık Tic. Ltd. Sti; 2005. Gross DR. Animal Models in Cardiovascular Research. 2nd Revised ed. Boston: Kluwer Academic; 1994.
  2. Wolkart G, Kaber G, Kojda G, Brunner F. Role of endogenous hydrogen peroxide in cardiovascular ischaemia/reperfusion function. Studies in mouse hearts with catalase-overexpression in the vascular endothelium. Pharmacol Res 2006; 54:50-56.
  3. Gonon AT, Bulhak A, Broijersen A, Pernow J. Cardioprotective effect of an endothelin receptor antagonist during ischaemia/reperfusion in the severely atherosclerotic mouse heart. Br J Pharmacol 2005; 144:860-866.
  4. Ashton KJ, Willems L, Holmgren K, Ferreira L, Headrick JP. Age-associated shifts in cardiac gene transcription and transcriptional responses to ischemic stress. Exp Gerontol 2006; 41:189-204. du Toit EF, Rossouw E, Salie R, Opie LH, Lochner A. Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 2005; 19:23-31.
  5. Lochner A, Genade S, Hattingh S, Marais E, Huisamen B, Moolman JA. Comparison between ischaemic and anisomycin-induced preconditioning: Role of p38 MAPK. Cardiovasc Drugs Ther 2003; 17:217-230.
  6. Khudairi T, Khaw BA. Preservation of ischemic myocardial function and integrity with targeted cytoskeleton-specific immunoliposomes. J Am Coll Cardiol 2004; 43:1683-1689.
  7. Ikizler M, Dernek S, Sevin B, Kural T. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia. Anadolu Kardiyol Derg 2003; 3:303-308.
  8. Wischmeyer PE, Jayakar D, Williams U, Singleton KD, Riehm J, Bacha EA, et al. Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia reperfusion injury. J Parenter Enteral Nutr 2003; 27(6):396-403.
  9. Takahashi N, Ooie T, Saikawa T, Iwao T, Yoshimatsu H, Sakata T. Long-term treatment with glibenclamide increases susceptibility of streptozotocin-induced diabetic rat heart to reperfusioninduced ventricular tachycardia. Exp Biol Med (Maywood) 2003; 228:1234-1238.
  10. Ooie T, Takahashi N, Nawata T, Arikawa M, Yamanaka K, Kajimoto M, et al. Ischemia-induced translocation of protein kinaseC-epsilon mediates cardioprotection in the streptozotocin-induced diabetic rat. Circ J 2003; 67:955-961.
  11. Dernek S, Ikizler M, Erkasap N, Ergun B, Koken T, Yilmaz K, et al. Cardioprotection with resveratrol pretreatment:Improved beneficial effects over standard